Free Trial
Register for our free email digests:
|
|
||
 |
William LooneyExecutive Editor |
William Looney is Executive Biopharma Editor of In Vivo, where he provides opinion and feature-length reports on C-suite leadership, commercial strategy, medicines research, and corporate reputation and policy. He has a broad background in the industry, with prior positions as an analyst at The Economist Intelligence Unit, senior director for Pfizer Inc., and Editor-in-Chief at Pharmaceutical Executive. He is the recipient of several awards for editorial commentary and business journalism. |
|
|
||
 |
Ashley YeoExecutive Editor |
Ashley Yeo is an editor of the medtech titles within Informa's Pharma Insights division. As Executive Medtech Editor of In Vivo, Ashley writes and commissions insight and features to meet the strategic business and market access information needs of device makers and other health care stakeholders in the global medtech market. He also contributes news and insight needs to the group's other major medtech title, Medtech Insight on market access and OUS/global themes. Ashley joined one of Informa's precursor companies in 1988 as French and German news reporter. He has been chief editor of three of the group's multi-industry titles and was a founding member of the cross-industry Principal Analyst team. |
 |
John HodgsonExecutive Editor |
John is Data Editor, Pharma within Informa’s Pharma Intelligence division. He honed skills as a writer, analyst and consultant, commentating on science and business in biotechnology over three decades. He prefers evidence to received wisdom, and believes that new is interesting but improved is better. |
 |
Peter CharlishSenior Editor |
Peter originally trained as a pharmacologist and has been following the fortunes of the pharmaceutical and medtech industries for over 35 years. During that time he has interviewed many people, attended many conferences and trade shows, and has visited companies large and small. He has written items for newsletters, feature articles for magazines, as well as longer in-depth reports. He has also spoken on healthcare-related matters at a number of international conferences. Out of all that has come a passion to understand what drives individuals and organisations to push back the frontiers of knowledge for the overall benefit of mankind. In his spare time he likes to complain about falling standards (grammar, manners, road users who don’t indicate), and he has little time for those who use management gobbledegook. |
 |
Amanda MicklusPrincipal Analyst |
Amanda has been tracking corporate strategy and business development activities in the biopharma and medtech industries for more than 10 years. She is a principal analyst with Informa’s Datamonitor Healthcare where she researches and analyzes trends in corporate strategy and dealmaking, and compiles reports for clients. Amanda also writes trends pieces for Informa’s IN VIVO and START-UP publications, and contributes to Informa’s Strategic Transactions deals database, researching and writing analyses on individual biopharma and medtech transactions. Before joining Informa, Amanda spent five years at Purdue Pharma, working as a market research analyst and information searcher. She has a Bachelor of Science degree in Chemistry-Business from the University of Scranton, and a Master of Science in Library & Information Science from Long Island University. |
 |
Karen ColemanHead of In Vivo |
Karen has 17 years' experience in the pharmaceutical world. She qualified as a pharmacist in South Africa where she worked in retail and hospital settings before relocating to the UK in 2002. After some months in hospital pharmacy Karen entered the world of business information via IMS Health (now Quintiles IMS), analyzing patent expiries and generic drug launches in 26 major and emerging markets. Karen joined Informa in 2009, leading a team of analysts publishing Strategic reports covering numerous aspects of the Pharma and Medtech industries. She has successfully contributed to the Pharma Intelligence division in a number of roles, and is currently Head of In Vivo – a publication with a 35-year history of providing best in class strategic insight to C-suite executives. |
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.